Stock Price Quote

NEULAND LABORATORIES LTD.

NSE : NEULANDLABBSE : 524558ISIN CODE : INE794A01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE16295.85-376.3 (-2.26 %)
PREV CLOSE ( ) 16672.15
OPEN PRICE ( ) 16747.55
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1073
TODAY'S LOW / HIGH ( )16211.90 16747.55
52 WK LOW / HIGH ( )10060 19748.4
NSE16299.00-375 (-2.25 %)
PREV CLOSE( ) 16674.00
OPEN PRICE ( ) 16673.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 16299.00 (12)
VOLUME 31039
TODAY'S LOW / HIGH( ) 16200.00 16727.00
52 WK LOW / HIGH ( )10190.7 19747
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 07-01 1984
Management Info
Davuluri Rama Mohan Rao - Chairman Davuluri Saharsh Rao - Managing Director
Registered Office

Address 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee Hills,
Hyderabad,
Telangana-500033

Phone 040-67611600 / 67611700

Email neuland@neulandlabs.com

Website www.neulandlabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

08Dec Neuland Laboratories informs about re-
Pursuant to SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 date..
26Nov Neuland Laboratories informs about ne
Pursuant to Regulation 47 of the Securities and Exchange Board of India..
28Oct Neuland Laboratories informs about ear
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..
03Sep Neuland Laboratories informs about new
Pursuant to Regulation 47 of the Securities and Exchange Board of India..
12Aug Neuland Laboratories informs about los
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations & Disc..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit964.62594.26
Gross Profit 1290.42 3453.74
Operating Profit 1569.223428.08
Net Sales 5142.7314768.37

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Procter&Gamble Healt (BSE)
peergroup  5694.85 (1.04%)
M.Cap ( in Cr)9453.10
Haleos Labs (BSE)
peergroup  1385.00 (3.40%)
M.Cap ( in Cr)418.73
Pfizer (BSE)
peergroup  5027.50 (0.90%)
M.Cap ( in Cr)22999.67
Venus Remedies (BSE)
peergroup  786.50 (5.00%)
M.Cap ( in Cr)1051.31
Ajanta Pharma (BSE)
peergroup  2655.30 (1.37%)
M.Cap ( in Cr)33174.16

Shareholding Pattern

MUTUAL FUNDS/UTI 9.78%
NON-INSTITUTION 32.81%
PROMOTERS 32.64%
FI/BANKS/INSURANCE 1.26%
GOVERNMENT 0.4%
FII 0%

About Neuland Laboratories Ltd.

Neuland Laboratories Ltd. was incorporated in the year 1984. Its today's share price is 16295.85. Its current market capitalisation stands at Rs 20907.39 Cr. In the latest quarter, company has reported Gross Sales of Rs. 14768.37 Cr and Total Income of Rs.14973.46 Cr. The company's management includes Ravi Shankar Gopinath, Sarada Bhamidipati, Pallavi Joshi Bakhru, Sugata Sircar, Prasad Raghava Menon, Christopher M Cimarusti, Davuluri Saharsh Rao, Homi Rustam Khusrokhan, Davuluri Sucheth Rao, Davuluri Rama Mohan Rao.

It is listed on the BSE with a BSE Code of 524558 , NSE with an NSE Symbol of NEULANDLAB and ISIN of INE794A01010. It's Registered office is at 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee HillsHyderabad-500033, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are KS Aiyar & Co, MSKA & Associates, Walker Chandik & Co LLP, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.